Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists - Takeaways - MDSpire

Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists

  • By

  • Yu-Cheng Chang

  • Chun-Yu Peng

  • Kuan-Yu Chi

  • Junmin Song

  • Yu Chang

  • Cho-Hung Chiang

  • Wenli Gao

  • Cho-Han Chiang

  • January 29, 2025

  • 0 min

Share

  • 1

    GLP1a use is linked to a significant reduction in major adverse cardiovascular events among multiple myeloma patients with Type 2 diabetes.

  • 2

    Patients on GLP1a experienced a 43% lower risk of heart failure compared to those on non-GLP1a diabetes medications.

  • 3

    The study found a 44% lower risk of all-cause mortality in patients using GLP1a compared to those using other diabetes medications.

  • 4

    No increased risk of adverse events was associated with GLP1a use in the studied population of multiple myeloma patients.

  • 5

    The research utilized a propensity score-matched cohort study design to ensure balanced comparison between GLP1a and non-GLP1a groups.

Original Source(s)

Cardiovascular outcomes and mortality in diabetic multiple myeloma patients initiated on proteasome inhibitors according to prior use of glucagon-like peptide 1 agonists

  • by Yu-Cheng Chang, Chun-Yu Peng, Kuan-Yu Chi, Junmin Song, Yu Chang, Cho-Hung Chiang, Wenli Gao, Cho-Han Chiang

  • January 29, 2025

Related Content

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Case Report: Selective metal cell excision during open TAVR implantation preserves coronary access while maintaining valve integrity and function

Biomolecular mechanisms of cardiac amyloidosis and its cardiovascular pathological basis